🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Exploring Blood Cell Function and Oxidative Stress to Improve Diagnosis and Treatment in Pre-Capillary Pulmonary Hypertension

Recruitingn/aAges 18 Years - anyAllUniversity Hospital, Strasbourg, France
NCT07176260 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to understand how blood cell (including peripheral blood mononuclear cells ((PBMCs) or platelets) function and oxidative stress can help physicians detect and predict the course of pre-capillary pulmonary hypertension. We hypothesize that changes in the mitochondrial function of blood cells and oxidative stress may be early markers of disease progression and severity. The study will also explore how these blood markers relate to routine clinical and heart function measurements, such as echocardiography, right heart catheterization, 6-minute walk tests, and functional status, to see if they can help monitor patients over time and guide personalized care. This is a non-interventional study. Blood samples will be collected during routine visits planned for diagnosis and follow-up. The study will include 120 patients diagnosed with pre-capillary pulmonary hypertension, who

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adult patients (≥18 years) diagnosed with pre-capillary pulmonary hypertension confirmed by right heart catheterization * Patients classified according to the international clinical classification: * Group 1: Pulmonary arterial hypertension (PAH) * Group 3: Pulmonary hypertension associated with chronic respiratory diseases and/or hypoxia * Group 4: Chronic thromboembolic pulmonary hypertension (CTEPH) * Patients scheduled for routine clinical follow-up and/or right heart catheterization at the study center. * Ability and willingness to provide informed consent for participation and data analysis. Exclusion Criteria: * Postcapillary pulmonary hypertension (pulmonary arterial wedge pressure \>15 mmHg). * Conditions precluding safe blood sampling (e.g., severe anemia, coagulopathy). * Patients already enrolled in interventional clinical trials that could interfere with mitochondrial or oxidative stress measurements * Patients unable or unwilling to provide informed consent * Pregnancy or breastfeeding
💊

What it tests

  • Patients with pre-Capillary pulmonary hypertension
📍

Where

1 site
Hôpitaux Universitaires de Strasbourg - Service Physiologie explorations fonctionnelles
Strasbourg, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy